Issues facing brand teams and how agencies help to deliver value
|2nd March 2016
At Blue Latitude Health, we place a lot of importance on establishing and maintaining long-term, value-adding relationships with our clients. As a result of our continued focus on building trust and delivering results for Janssen, back in September 2015 we were re-appointed for another three years to provide strategic support and creative marketing services for their brand teams in the EMEA region.
We interviewed Wayne Atherden, Procurement Director Commercial Services at Janssen, our European procurement contact, to get a fuller understanding of his view on the issues facing brand teams and how agencies help to deliver value. Here is what he had to say.
Q: Digital and multichannel marketing has clearly changed the way that marketing brand teams work. Can you tell us a bit more about how this has affected brand teams at Janssen?
Wayne: The shift has highlighted even more acutely the need to better understand our customers – where do they go for information, how do they prefer to interact with pharma companies, how do they get answers to their questions? We need to customise the channels we use to the type of healthcare professional (HCP), so as to optimise our investments and maximise impact.
As options have multiplied, we need to be more discerning, to focus on areas that really make a difference. Our agencies have a key role in helping us achieve this, by using market and customer insights to help shape our strategies.
Read the full interview in our special supplement to Perspective magazine.
Precision paediatrics: Treating patients with CAR-T
|9th July 2019
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality
What does it mean to be an agile organisation
|27th June 2019
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market.
Battling breast cancer with precision medicine (Part 2)
|20th June 2019
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives his side of the story and explains how industry can help oncologists treat more patients with targeted therapies.